Kidney Cancer Clinical Trials

82 recruitingLast updated: June 17, 2026

There are 82 actively recruiting kidney cancer clinical trials across 27 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Lyon, France, Houston, Texas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Kidney Cancer Trials at a Glance

82 actively recruiting trials for kidney cancer are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Not Applicable with 20 trials, with the heaviest enrollment activity in Lyon, Houston, and Boston. Lead sponsors running kidney cancer studies include National Cancer Institute (NCI), Gustave Roussy, Cancer Campus, Grand Paris, and Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Browse kidney cancer trials by phase

Treatments under study

About Kidney Cancer Clinical Trials

Looking for clinical trials for Kidney Cancer? There are currently 64 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Kidney Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Kidney Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 82 trials

Recruiting

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Bladder CancerKidney CancerRenal Cancer+2 more
National Cancer Institute (NCI)5,950 enrolled1 locationNCT00026884
Recruiting

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Kidney CancerRenal Tumor HistologyCutaneous Leiomyoma
National Cancer Institute (NCI)1,130 enrolled1 locationNCT00050752
Recruiting

Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

Kidney CancerKidney NeoplasmsPneumothorax+1 more
National Cancer Institute (NCI)950 enrolled1 locationNCT00033137
Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Nasopharyngeal CarcinomaKidney CancersEsthesioneuroblastoma+7 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Not Applicable

A Study of a Side Effects and Resource Navigation Program for People With Cancer

Breast CancerLung CancerBladder Cancer+1 more
Memorial Sloan Kettering Cancer Center200 enrolled8 locationsNCT07646847
Recruiting

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Breast CancerColorectal, CancerProstate Cancer+9 more
University Health Network, Toronto500 enrolled3 locationsNCT05403177
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 4

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Metastatic Renal Cell CarcinomaLocally AdvancedRenal Cell Carcinoma (Kidney Cancer)
Centre Francois Baclesse83 enrolled16 locationsNCT07028125
Recruiting
Not Applicable

Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

Prostate CancerKidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins90 enrolled2 locationsNCT06138067
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Renal Cell CarcinomaClear Cell Renal Cell CarcinomaKidney Cancers+6 more
Neomorph, Inc30 enrolled10 locationsNCT07300241
Recruiting

UroCCR Database: French Research Network for Kidney Cancer -UroCCR

Kidney Cancer
University Hospital, Bordeaux30,000 enrolled68 locationsNCT03293563
Recruiting

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

Renal Cell CarcinomaKidney CancerClear Cell Renal Cancer+2 more
National Cancer Institute (NCI)5,000 enrolled1 locationNCT00001238
Recruiting

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Breast CancerLiver CancerPancreatic Cancer+6 more
University of Sydney300 enrolled4 locationsNCT05184790
Recruiting
Phase 1

Drug Screening Using Novel IMD in Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaRenal Cell CarcinomaKidney Cancer
Oliver Jonas20 enrolled1 locationNCT05700461
Recruiting
Phase 1

Brodalumab in the Treatment of Immune-Related Adverse Events

Breast CancerLiver CancerEsophageal Cancer+15 more
Brian Henick, MD11 enrolled1 locationNCT06673329
Recruiting
Early Phase 1

Clinical Application of CAIX-Targeted PET Imaging in Tumors

Kidney Cancers
Peking University Cancer Hospital & Institute3 enrolled1 locationNCT07590310
Recruiting
Not Applicable

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

Non-small Cell Lung CancerMelanoma (Skin Cancer)Invasive Mammary Carcinoma+5 more
Jessica Mezzanotte Sharpe25 enrolled1 locationNCT07555210
Recruiting

Integrated Cancer Repository for Cancer Research

Breast CancerLiver CancerEsophageal Cancer+47 more
University of Nebraska999,999 enrolled42 locationsNCT02012699
Recruiting

TDM for Optimized Outcome in Patients With mRCC.

Renal Cell Carcinoma MetastaticKidney CancerDrug Toxicity+2 more
Niels Fristrup200 enrolled1 locationNCT04659343